Free Newsletter
NIH funnels $533M into translational research work
The Scripps Transitional Research Institute was one of 14 research groups that will gain $533 million from the NIH over five years. The funds are earmarked to speed the development of new technologies. Scripps will get $20 million over five years to advance work on genomics. The acclaimed geneticist Eric Topol runs the program at Scripps. The Clinical Translation Science Award was set up in 2006, giving researchers a great deal of freedom in determining how the money is spent.
Among other recipients, medical researchers at The Ohio State University, in partnership with Nationwide Children's Hospital, received a $34 million grant. Other institutions awarded with a fund from the NIH included Albert Einstein College of Medicine at Yeshiva University in New York City; Boston University; the Stanford University School of Medicine; Harvard University; Indiana University School of Medicine; Northwestern University; Tufts University; the University of Alabama at Birmingham; the University of Colorado, Denver; the University of North Carolina, Chapel Hill; the University of Texas Health Science Center at San Antonio and the University of Utah.
- check out the release
- read the report from the San Diego Union-Tribune
ALSO: After a lengthy delay, the NIH unveiled its new $278 million research facility in Baltimore. More than 80 scientists won't be able to move to the facility because vibrations in the structure would skew data. Report
Comments
Its great these groups are spending all this money on these facilities but NIH still retains all their own work. Only releasing their information years after the work has been completed. Thus all these groups are ten years behind NIH's own research teams.
Maynezfoundation.org has been established and approved to do business with NIH. Maynezfoundation.org will supply plasma to any group interested in the actual production of an aids vaccine.
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact




